866-997-4948(US-Canada Toll Free)

Vulvar Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : May 2016

Category :

Cancer

No. of Pages : 73 Pages

Vulvar Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Vulvar Cancer - Pipeline Review, H1 2016, provides an overview of the Vulvar Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vulvar Cancer
- The report reviews pipeline therapeutics for Vulvar Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vulvar Cancer therapeutics and enlists all their major and minor projects
- The report assesses Vulvar Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vulvar Cancer


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vulvar Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vulvar Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vulvar Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Vulvar Cancer - Overview 7
Pipeline Products for Vulvar Cancer - Comparative Analysis 8
Vulvar Cancer - Therapeutics under Development by Companies 9
Vulvar Cancer - Therapeutics under Investigation by Universities/Institutes 10
Vulvar Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Vulvar Cancer - Products under Development by Companies 12
Vulvar Cancer - Products under Investigation by Universities/Institutes 13
Vulvar Cancer - Companies Involved in Therapeutics Development 14
ISA Pharmaceuticals B.V. 14
Ono Pharmaceutical Co., Ltd. 15
Oryx GmbH & Co. KG 16
PDS Biotechnology Corporation 17
Vulvar Cancer - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ISA-101 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
nivolumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
omiganan pentahydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PDS-0101A - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vicoryx - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Vulvar Cancer - Recent Pipeline Updates 43
Vulvar Cancer - Dormant Projects 69
Vulvar Cancer - Product Development Milestones 70
Featured News & Press Releases 70
Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 70
Mar 07, 2011: ISA Pharma Receives 2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 70
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 70
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables
Number of Products under Development for Vulvar Cancer, H1 2016 7
Number of Products under Development for Vulvar Cancer - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Products under Investigation by Universities/Institutes, H1 2016 13
Vulvar Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 14
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 15
Vulvar Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 16
Vulvar Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Vulvar Cancer Therapeutics - Recent Pipeline Updates, H1 2016 43
Vulvar Cancer - Dormant Projects, H1 2016 69

List of Figures
Number of Products under Development for Vulvar Cancer, H1 2016 7
Number of Products under Development for Vulvar Cancer - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Targets, H1 2016 19
Number of Products by Stage and Targets, H1 2016 19
Number of Products by Mechanism of Actions, H1 2016 21
Number of Products by Stage and Mechanism of Actions, H1 2016 21
Number of Products by Routes of Administration, H1 2016 23
Number of Products by Stage and Routes of Administration, H1 2016 23
Number of Products by Molecule Types, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *